TAM KALINLIKTA NASAL ALAR DEFEKTİN KOMPOZİT KULAK GREFTİ ve HİPERBARİK OKSİJEN TEDAVİSİ İLE ONARIMI

Year 2008, Volume: 21 Issue: 3, 296 - 297, 24.06.2015

Yakup Çil , Mehmet Sezgin

Abstract

Nasal alar bölge defektlerinin estetik ve fonksiyonel açıdan onarımının yapılması cerrah için oldukça zordur. Literatürde değişik teknikler tarif edilmiş olsada, ideal onarım tekniği mevcut değildir. Biz kompozit kulak grefti ile hiperbarik oksijen tedavisini kombine olarak 21 yaşındaki erkek hastadaki nasal alar defekti için kullandık. Kompozit kulak grefti hiperbarik oksijen tedavisi ile kombine edilerek tam kalınlıktak nasal alar defektlerin onarımında kullanıldığında iyi fonksiyonel ve estetik sonuç sağlanabilir.

Keywords

Nasal Alar Defekt, Kompozit Greft, Hiperbarik Oksijen

References

• 1. Svedman P. Advancement flaps for alar reconstruction. Ann Plast Surg 1990;25(6):502-7.
• 2. Burget GC, Menick FJ. The subunit principle in nasal reconstruction. Plast Reconstr Surg 1985;76(2):239-47.
• 3. Keck T, Lindemann J, Kuhnemann S, et al. Healing of composite chondrocutaneous auricular grafts covered by skin flaps in nasal reconstructive surgery. Laryngoscope 2003;113(2):248-53.
• 4. Lewis D, Goldztein H, Deschler D. Use of hyperbaric oxygen to enhance auricular composite graft survival in the rabbit model. Arch Facial Plast Surg 2006;8(5):310- 13.
• : 165-176.
• Koch AE, Harlow LA, Haines GK, et al. Vascular
• endothelial growth factor. A cytokine modulating
• endothelial function in reumatoid arthritis, J Immunol
• ; 152 (8): 4149-4156.
• Miller JW, Adamis AP, Aiello LP. Vascular
• endothelial growth factor in ocular neovascularization
• and proliferative diabetic retinopathy. Diabetes Metab
• Rev 1997; 13; 37-50.
• Saaristo A, Karpanen T, Alitalo K. Mechanisms of
• angiogenesis and their use in the ınhibition of tumor
• growth and metastasis. Oncogene 2000; 19: 6122-
• -
• Davis S, Aldrich TH, Jones PF, Acheson A, Compton
• DL, Jain V, et al. Isolation of angiopoietin-1, a ligand
• for the tie2 receptor, by secretion-trap expression
• cloning. Cell 1996; 87 (7): 1161-1169.
• Maisonpierre PC, Suri C, Jones PF, et al.
• Angiopoietin-2, a natural antagonist for Tie2 that
• disrupts in vivo angiogenesis. Science 1997; 277
• (5322): 55-60.
• Konac E, Onen HI, Metindir J, Alp E, Biri AA,
• Ekmekci A. Lack of association between -460 C/T
• and 936 C/T of the vascular endothelial growth factor
• and angiopoietin-2 exon 4 G/A polymorphisms and
• ovarian, cervical, and endometrial cancers. DNA Cell
• Biol 2007; 26: 453-463.
• Onen IH, Konac E, Eroglu M, Guneri C, Biri H,
• Ekmekci A. No association between polymorphism in
• the vascular endothelial growth factor gene at
• position-460 and sporadic prostate cancer in the
• Turkish population. Mol Biol Rep 2008; 1: 17-22.
• Wang GL, Semenza GL. Purification and
• characterization of hypoxia-inducible factor 1. J Biol
• Chem 1995; 270: 1230–1237.
• Konac E, Onen HI, Metindir J, Alp E, Biri AA,
• Ekmekci A. An investigation of relationships between
• hypoxia-inducible factor-1 alpha gene polymorphisms
• and ovarian, cervical and endometrial cancers. Cancer
• Detect Prev 2007; 31: 102-109.
• Vogelstein B, Kinzler KW. Cancer genes and the
• pathways they control. Nat Med 2004; 10: 789–799.
• Hartsough MT, Steeg PS. Nm23/nucleoside
• diphosphate kinase in human cancers. J Bioenerg
• Biomembr 2000; 32 (3): 301-308.
• Fearon ER. Human cancer syndromes: clues to the
• origin and nature of cancer. Science 1997; 278: 1043-
• -
• Ghilardi G, Biondi ML, Caputo M, et al. A single
• nucleotide polymorphism in the matrix
• metalloproteinase-3 promoter enhances breast cancer
• -
• Marmara Medical Journal 2008;21(3);282-295
• Abdullah Ekmekçi ve Ark.
• Gen polimorfizmi ve kansere yatkınlık
• susceptibility. Clinical Cancer Res 2002; 8 (12):
• -3823.
• Ghilardi G, Biondi ML, Erario M, Guagnellini E,
• Scorza R. Colorectal carcinoma susceptibility and
• metastases are associated with matrix
• metalloproteinase-7 promoter polymorphisms. Clinic
• Chem 2003; 49: 1940-1942.
• Eroglu A, Ulu A, Cam R, Akar N. Plasminogen
• activator inhibitor-1 gene 4G/5G polymorphism in
• patients with breast cancer. J BUON 2006; 11: 481-
• -
• Lei H, Hemminki K, Johansson R, Altieri A, Enquist
• K, Henriksson R, et al. PAI-1 -675 4G/5G
• polymorphism as a prognostic biomarker in breast
• cancer, Breast Cancer Res Treat, DOI:
• 1007/s10549-007-9635-3 July 7; 2007.
• van den Bemd GJ, Pols HA, van Leeuwen JP. Antitumor
• effects of 1,25-dihydroxyvitamin D3 and
• vitamin D analogs. Curr Pharm Des 2000; 6: 717-732.
• Haussler MR, Whitfield GK, Haussler CA. The
• nuclear vitamin D receptor: biological and molecular
• regulatory properties revealed. J Bone Miner Res
• ; 1: 325– 349.
• Drocourt L, Ourlin JC, Pascussi JM, Maurel P,
• Vilarem MJ. Expression of CYP3A4, CYP2B6, and
• CYP2C9 is regulated by the vitamin D receptor
• pathway in primary human hepatocytes. J Biol Chem
• ; 277: 25125–25132.
• Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J
• Physiol Renal Physiol 1999; 277: F157–175.
• Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA,
• Van Leeuwen JP. Genetics and biology of vitamin D
• receptor polymorphisms. Gene 2004; 338: 143–156.
• Obara W, Suzuki Y, Kato K, Tanji S, Konda R,
• Fujioka T. Vitamin D receptor gene polymorphisms
• are associated with increased risk and progression of
• renal cell carcinoma in a Japanese population. Int J
• Urol 2007; 14: 483-487.
• Taylor JA, Hirvonen A, Watson M, Pittman G,
• Mohler JL, Bell DA. Association of prostate cancer
• with vitamin D receptor gene polymorphism. Cancer
• Res 1996; 56: 4108-4110.
• Kadiyska T, Yakulov T, Kaneva R, Nedin D,
• Alexandrova A, Gegova A, et al. Vitamin D and
• estrogen receptor gene polymorphisms and the risk of
• colorectal cancer in Bulgaria. Int J Colorectal Dis
• ; 22 (4): 395-400.
• Lundin AC, Söderkvist P, Eriksson B, BergmanJungeström
• M, Wingren S. Association of breast
• cancer progression with a vitamin D receptor gene
• polymorphism. South-East Sweden Breast Cancer
• Group. Cancer Res 1999; 59: 2332-2334.
• Oakley-Girvan I, Feldman D, Eccleshall TR,
• Gallagher RP, Wu AH, Kolonel LN, et al. Risk of
• early-onset prostate cancer in relation to germ line
• polymorphisms of the vitamin D receptor. Cancer
• Epidemiol Biomarkers Prev 2004; 13 (8): 1325-1330.
• Morrison NA, Yeoman R, Kelly PJ, Eisman JA.
• Contribution of trans-acting factor alleles to normal
• physiological variability: vitamin D receptor gene
• polymorphism and circulating osteocalcin. Proc Natl
• Acad Sci USA 1992; 89: 6665-6669.
• Faraco JH, Morrison NA, Baker A, Shine J, Frossard
• PM. ApaI dimorphism at the human vitamin D
• receptor gene locus. Nucleic Acids Res 1989; 17:
• -
• Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L,
• Nguyen TV, et al. Prediction of bone density from
• vitamin D receptor alleles. Nature 1994; 367 (6460):
• -287.
• Onen HI, Ekmekci A, Eroğlu M, Konac E, Yeşil S,
• Biri H: Association of genetic polymorphisms in
• vitamin D receptor gene and susceptibility to sporadic
• prostate cancer. Exp Biol Med 2008; 233 (12): In
• Press.